LAVA Therapeutics (LVTX) Stock Chart & Stock Price History $1.43 +0.03 (+2.14%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LAVA Therapeutics Stock Price Performance The LAVA Therapeutics (LVTX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 32.23%, with a year-to-date return of 50.37%. In the past month, the stock has increased 10.85%, reflecting recent market activity. As of the latest close, LAVA Therapeutics traded at $1.40 with a market cap of $36.83 million and volume of 29,082 shares. Receive LVTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+5.15%1 Month Performance+10.85%3 Month Performance+16.26%Year-To-Date Performance+50.37%1 Year Performance-32.23% LVTX Stock Chart for Wednesday, July, 16, 2025 LVTX Chart by TradingView LAVA Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/15/2025$1.48$1.40-5.41%$1.45$1.3929,082 shs$36.83 million07/14/2025$1.36$1.48+8.82%$1.49$1.38152,257 shs$38.93 million07/11/2025$1.35$1.36+0.74%$1.38$1.3413,995 shs$35.78 million07/10/2025$1.36$1.35-0.74%$1.37$1.338,907 shs$35.52 million07/09/2025$1.36$1.36+0.23%$1.40$1.319,242 shs$35.78 million07/08/2025$1.32$1.36+2.80%$1.38$1.3111,816 shs$35.70 million07/07/2025$1.34$1.32-1.12%$1.35$1.3019,404 shs$34.72 million07/04/2025$1.34$1.34$1.34$1.303,996 shs$35.12 million07/03/2025$1.31$1.34+1.91%$1.34$1.303,996 shs$35.12 million07/02/2025$1.34$1.31-2.17%$1.38$1.3019,864 shs$34.47 million Get the Latest News and Ratings for LVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/01/2025$1.32$1.34+1.44%$1.35$1.3120,027 shs$35.23 million06/30/2025$1.31$1.32+0.76%$1.32$1.2913,057 shs$34.73 million06/27/2025$1.31$1.31+0.38%$1.33$1.2911,959 shs$34.47 million06/26/2025$1.31$1.31-0.71%$1.31$1.277,743 shs$34.34 million06/25/2025$1.33$1.31-0.88%$1.33$1.297,179 shs$34.57 million06/24/2025$1.33$1.33+0.08%$1.34$1.295,765 shs$34.89 million06/23/2025$1.31$1.33+1.15%$1.34$1.304,822 shs$34.86 million06/20/2025$1.30$1.31+1.08%$1.38$1.3015,523 shs$34.47 million06/19/2025$1.30$1.30$1.34$1.2820,048 shs$34.10 million06/18/2025$1.30$1.30-0.31%$1.34$1.2820,048 shs$34.10 million06/17/2025$1.29$1.30+0.78%$1.32$1.308,966 shs$34.20 million06/16/2025$1.31$1.29-1.53%$1.31$1.286,830 shs$33.93 million Related Companies Galectin Therapeutics Stock Price Chart Greenwich LifeSciences Stock Price Chart Rapt Therapeutics Stock Price Chart Neumora Therapeutics Stock Price Chart FitLife Brands Stock Price Chart Actuate Therapeutics Stock Price Chart Fate Therapeutics Stock Price Chart Caribou Biosciences Stock Price Chart Cardiol Therapeutics Stock Price Chart Korro Bio Stock Price Chart Receive LVTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:LVTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
